Neurokinin 3 Receptor Antagonists for Menopause Symptom Management.

Neurokinin (NK) receptor antagonists represent a significant advancement in nonhormonal treatment of vasomotor symptoms (VMS) by targeting the underlying neuronal pathways driving thermoregulatory dysfunction. Fezolinetant, a selective NK 3 receptor antagonist, and elinzanetant, a dual NK1/NK3 receptor antagonist, provide rapid and clinically meaningful reductions in VMS, with elinzanetant offering additional improvements in sleep. Both agents show favorable safety profiles, and elinzanetant is supported for use in women receiving endocrine therapy for breast cancer. Ongoing research explores broader applications in metabolic health and individualized therapy.